Captopril reduces functional mitral regurgitation in patients with dilated heart failure. A randomized double-blind placebo-controlled trial of 28 patients with NYHA class II or III heart failure and functional mitral regurgitation showed that captopril significantly reduced mitral regurgitant area, stroke volume, and systemic vascular resistance, with the most significant improvements at 100 mg/day. Captopril also improved left atrial area, deceleration time, and Duke activity index score. These effects were not seen in the placebo group. The study concluded that captopril is effective in reducing functional mitral regurgitation in dilated heart failure, and patients require and must tolerate high doses (50–100 mg/day) for additive effects over conventional treatment to occur. The study also showed that captopril is well tolerated, with no significant side effects. The results suggest that captopril is a valuable treatment option for patients with dilated heart failure and functional mitral regurgitation. The study highlights the importance of using high doses of captopril to achieve significant improvements in patients with dilated heart failure. The study also emphasizes the need for further research to determine the optimal dose of captopril for dilated heart failure. The study also highlights the importance of using Doppler echocardiography to assess the effectiveness of captopril in reducing functional mitral regurgitation. The study also shows that captopril is effective in reducing functional mitral regurgitation in patients with dilated heart failure, and that high doses are necessary to achieve significant improvements. The study also shows that captopril is well tolerated, with no significant side effects. The study also highlights the importance of using high doses of captopril to achieve significant improvements in patients with dilated heart failure. The study also emphasizes the need for further research to determine the optimal dose of captopril for dilated heart failure. The study also highlights the importance of using Doppler echocardiography to assess the effectiveness of captopril in reducing functional mitral regurgitation.Captopril reduces functional mitral regurgitation in patients with dilated heart failure. A randomized double-blind placebo-controlled trial of 28 patients with NYHA class II or III heart failure and functional mitral regurgitation showed that captopril significantly reduced mitral regurgitant area, stroke volume, and systemic vascular resistance, with the most significant improvements at 100 mg/day. Captopril also improved left atrial area, deceleration time, and Duke activity index score. These effects were not seen in the placebo group. The study concluded that captopril is effective in reducing functional mitral regurgitation in dilated heart failure, and patients require and must tolerate high doses (50–100 mg/day) for additive effects over conventional treatment to occur. The study also showed that captopril is well tolerated, with no significant side effects. The results suggest that captopril is a valuable treatment option for patients with dilated heart failure and functional mitral regurgitation. The study highlights the importance of using high doses of captopril to achieve significant improvements in patients with dilated heart failure. The study also emphasizes the need for further research to determine the optimal dose of captopril for dilated heart failure. The study also highlights the importance of using Doppler echocardiography to assess the effectiveness of captopril in reducing functional mitral regurgitation. The study also shows that captopril is effective in reducing functional mitral regurgitation in patients with dilated heart failure, and that high doses are necessary to achieve significant improvements. The study also shows that captopril is well tolerated, with no significant side effects. The study also highlights the importance of using high doses of captopril to achieve significant improvements in patients with dilated heart failure. The study also emphasizes the need for further research to determine the optimal dose of captopril for dilated heart failure. The study also highlights the importance of using Doppler echocardiography to assess the effectiveness of captopril in reducing functional mitral regurgitation.